Literature DB >> 15322019

Involvement of the lectin pathway of complement activation in antimicrobial immune defense during experimental septic peritonitis.

Michaela Windbichler1, Bernd Echtenacher, Thomas Hehlgans, Jens C Jensenius, Wilhelm Schwaeble, Daniela N Männel.   

Abstract

A critical first line of defense against infection is constituted by the binding of natural antibodies to microbial surfaces, activating the complement system via the classical complement activation pathway. In this function, the classical activation pathway is supported and amplified by two antibody-independent complement activation routes, i.e., the lectin pathway and the alternative pathway. We studied the contribution of the different complement activation pathways in the host defense against experimental polymicrobial peritonitis induced by cecal ligation and puncture by using mice deficient in either C1q or factors B and C2. The C1q-deficient mice lack the classical complement activation pathway. While infection-induced mortality of wild-type mice was 27%, mortality of C1q-deficient mice was increased to 60%. Mice with a deficiency of both factors B and C2 lack complement activation via the classical, the alternative, and the lectin pathways and exhibit a mortality of 92%, indicating a significant contribution of the lectin and alternative pathways of complement activation to survival. For 14 days after infection, mannan-binding lectin (MBL)-dependent activation of C4 was compromised. Serum MBL-A and MBL-C levels were significantly reduced for 1 week, possibly due to consumption. mRNA expression profiles did not lend support for either of the two MBL genes to respond as typical acute-phase genes. Our results demonstrate a long-lasting depletion of MBL-A and MBL-C from serum during microbial infection and underline the importance of both the lectin and the alternative pathways for antimicrobial immune defense.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15322019      PMCID: PMC517465          DOI: 10.1128/IAI.72.9.5247-5252.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  52 in total

1.  Association of low levels of mannan-binding protein with a common defect of opsonisation.

Authors:  M Super; S Thiel; J Lu; R J Levinsky; M W Turner
Journal:  Lancet       Date:  1989-11-25       Impact factor: 79.321

Review 2.  Monocyte deactivation--rationale for a new therapeutic strategy in sepsis.

Authors:  H D Volk; P Reinke; D Krausch; H Zuckermann; K Asadullah; J M Müller; W D Döcke; W J Kox
Journal:  Intensive Care Med       Date:  1996-10       Impact factor: 17.440

3.  Characterization of human serum mannan-binding protein promoter.

Authors:  H Naito; A Ikeda; K Hasegawa; S Oka; K Uemura; N Kawasaki; T Kawasaki
Journal:  J Biochem       Date:  1999-12       Impact factor: 3.387

4.  Complement activation after oxidative stress: role of the lectin complement pathway.

Authors:  C D Collard; A Väkevä; M A Morrissey; A Agah; S A Rollins; W R Reenstra; J A Buras; S Meri; G L Stahl
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

5.  Cutting edge: complement-activating complex of ficolin and mannose-binding lectin-associated serine protease.

Authors:  M Matsushita; Y Endo; T Fujita
Journal:  J Immunol       Date:  2000-03-01       Impact factor: 5.422

6.  Purification and characterization of two mannan-binding lectins from mouse serum.

Authors:  S Hansen; S Thiel; A Willis; U Holmskov; J C Jensenius
Journal:  J Immunol       Date:  2000-03-01       Impact factor: 5.422

7.  A second serine protease associated with mannan-binding lectin that activates complement.

Authors:  S Thiel; T Vorup-Jensen; C M Stover; W Schwaeble; S B Laursen; K Poulsen; A C Willis; P Eggleton; S Hansen; U Holmskov; K B Reid; J C Jensenius
Journal:  Nature       Date:  1997-04-03       Impact factor: 49.962

8.  Serum lectin with known structure activates complement through the classical pathway.

Authors:  K Ikeda; T Sannoh; N Kawasaki; T Kawasaki; I Yamashina
Journal:  J Biol Chem       Date:  1987-06-05       Impact factor: 5.157

9.  Critical protective role of mast cells in a model of acute septic peritonitis.

Authors:  B Echtenacher; D N Männel; L Hültner
Journal:  Nature       Date:  1996-05-02       Impact factor: 49.962

10.  The human mannose-binding protein functions as an opsonin.

Authors:  M Kuhlman; K Joiner; R A Ezekowitz
Journal:  J Exp Med       Date:  1989-05-01       Impact factor: 14.307

View more
  7 in total

1.  Distinct different contributions of the alternative and classical complement activation pathway for the innate host response during sepsis.

Authors:  Katja Dahlke; Christiane D Wrann; Oliver Sommerfeld; Maik Sossdorf; Peter Recknagel; Svea Sachse; Sebastian W Winter; Andreas Klos; Gregory L Stahl; Yuanyuan Xu Ma; Ralf A Claus; Konrad Reinhart; Michael Bauer; Niels C Riedemann
Journal:  J Immunol       Date:  2011-01-24       Impact factor: 5.422

2.  Complement factor B is the downstream effector of TLRs and plays an important role in a mouse model of severe sepsis.

Authors:  Lin Zou; Yan Feng; Yan Li; Ming Zhang; Chan Chen; Jiayan Cai; Yu Gong; Larry Wang; Joshua M Thurman; Xiaobo Wu; John P Atkinson; Wei Chao
Journal:  J Immunol       Date:  2013-10-23       Impact factor: 5.422

3.  New insights for C5a and C5a receptors in sepsis.

Authors:  Chunguang Yan; Hongwei Gao
Journal:  Front Immunol       Date:  2012-12-10       Impact factor: 7.561

4.  Phytol-based novel adjuvants in vaccine formulation: 2. Assessment of efficacy in the induction of protective immune responses to lethal bacterial infections in mice.

Authors:  So-Yon Lim; Adam Bauermeister; Richard A Kjonaas; Swapan K Ghosh
Journal:  J Immune Based Ther Vaccines       Date:  2006-10-23

5.  Ficolins do not alter host immune responses to lipopolysaccharide-induced inflammation in vivo.

Authors:  Ninette Genster; Olga Østrup; Camilla Schjalm; Tom Eirik Mollnes; Jack B Cowland; Peter Garred
Journal:  Sci Rep       Date:  2017-06-20       Impact factor: 4.379

6.  C1q as a target molecule to treat human disease: What do mouse studies teach us?

Authors:  Kristina Schulz; Marten Trendelenburg
Journal:  Front Immunol       Date:  2022-08-03       Impact factor: 8.786

7.  The relative merits of therapies being developed to tackle inappropriate ('self'-directed) complement activation.

Authors:  Samuel Antwi-Baffour; Ransford Kyeremeh; Jonathan Kofi Adjei; Claudia Aryeh; George Kpentey
Journal:  Auto Immun Highlights       Date:  2016-03-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.